The shift towards value-based pricing for medicines
Interviewee/Contributor
Victoria English
Organisation
MedNous
Policy & Regulation
NCI and industry: Moving innovations from the lab to patients
Interviewee/Contributor
Michael Salgaller and Michele Newton
Organisation
US National Cancer Institute
The productivity of oncology development continues
Interviewee/Contributor
Bruno Pagliara
Organisation
On-kòs Pharma Consulting
IMI: Building a science infrastructure for Europe
Interviewee/Contributor
Pierre Meulien
Organisation
Innovative Medicines Initiative
Chimeric antigen receptor therapy goes global
Interviewee/Contributor
Carl June
Organisation
University of Pennsylvania, Perelman School of Medicine
EU Commission proposes €100 billion for science
Interviewee/Contributor
Peter Charlish
Organisation
MedNous
Innovation spreads across the oncology sector
Interviewee/Contributor
Bruno Pagliara
Organisation
On-kòs Pharma Consulting
Building a European capital market
Interviewee/Contributor
William Ellington
Organisation
Evernow Publishing Ltd
How GMO rules affect gene and cell therapies
Interviewee/Contributor
Houria Bachtarzi
Organisation
ERA Consulting (UK) Ltd
MedNous Briefing: FDA policy on digital health
Interviewee/Contributor
Peter Charlish
Organisation
MedNous